to-BB and the pharmaceutical company H. Lundbeck are entering into a research collaboration to evaluate delivery of antibodies to the brain for Central Nervous System (CNS) diseases
Leiden, The Netherlands | December 22, 2009 | to-BBB, the Dutch drug brain delivery company, and the pharmaceutical company H. Lundbeck A/S are entering into a research collaboration to evaluate delivery of antibodies to the brain for Central Nervous System (CNS) diseases. This research could provide the backbone of new emerging therapies for unserved brain diseases.
“We are very pleased to collaborate with Lundbeck,” says Pieter Gaillard, CSO of to-BBB. “to-BBB’s brain delivery technology combined with Lundbeck’s strong knowledge in the area of CNS disorders, should result in further progress to improve the lives of patients with devastating brain diseases.”
Lundbeck is an international pharmaceutical company engaged in research to find new drugs for treatment of CNS disorders, including depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease. The collaboration with to-BBB could provide Lundbeck with an opportunity to improve the brain delivery of therapeutic antibodies addressing CNS diseases.
Thanks to the advances of biotechnology, therapeutic antibodies have become well-established treatment modalities to address many systemic diseases. The blood-brain barrier (BBB) is unfortunately a significant obstacle in the treatment of CNS disorders, since it prevents delivery of many drug candidates to their disease target.
to-BBB’s proprietary G-Technology™ is a safe technology for drug delivery to the brain and is based on liposomes that are coated with the tripeptide glutathione at the tips of polyethylene glycol (PEG) to safely enhance the delivery of free drug to the brain. The company has shown proof of concept in several model systems, including brain microdialysis, pain inhibition, viral encephalitis and brain tumors, based on which Lundbeck will now evaluate the technology in their labs.
About to-BBB
to-BBB is a Dutch biotechnology company in the field of enhanced drug delivery across the blood-brain barrier. The company is developing novel treatments for brain disorders by combining existing drugs with its proprietary brain drug delivery platform. The company’s vision is that the treatment of currently unserved brain diseases will be best achieved by safely enhancing the blood-to-brain delivery of drugs.
to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and has established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.
SOURCE: to-BBB
Post Views: 72
to-BB and the pharmaceutical company H. Lundbeck are entering into a research collaboration to evaluate delivery of antibodies to the brain for Central Nervous System (CNS) diseases
Leiden, The Netherlands | December 22, 2009 | to-BBB, the Dutch drug brain delivery company, and the pharmaceutical company H. Lundbeck A/S are entering into a research collaboration to evaluate delivery of antibodies to the brain for Central Nervous System (CNS) diseases. This research could provide the backbone of new emerging therapies for unserved brain diseases.
“We are very pleased to collaborate with Lundbeck,” says Pieter Gaillard, CSO of to-BBB. “to-BBB’s brain delivery technology combined with Lundbeck’s strong knowledge in the area of CNS disorders, should result in further progress to improve the lives of patients with devastating brain diseases.”
Lundbeck is an international pharmaceutical company engaged in research to find new drugs for treatment of CNS disorders, including depression, schizophrenia, Alzheimer’s disease and Parkinson’s disease. The collaboration with to-BBB could provide Lundbeck with an opportunity to improve the brain delivery of therapeutic antibodies addressing CNS diseases.
Thanks to the advances of biotechnology, therapeutic antibodies have become well-established treatment modalities to address many systemic diseases. The blood-brain barrier (BBB) is unfortunately a significant obstacle in the treatment of CNS disorders, since it prevents delivery of many drug candidates to their disease target.
to-BBB’s proprietary G-Technology™ is a safe technology for drug delivery to the brain and is based on liposomes that are coated with the tripeptide glutathione at the tips of polyethylene glycol (PEG) to safely enhance the delivery of free drug to the brain. The company has shown proof of concept in several model systems, including brain microdialysis, pain inhibition, viral encephalitis and brain tumors, based on which Lundbeck will now evaluate the technology in their labs.
About to-BBB
to-BBB is a Dutch biotechnology company in the field of enhanced drug delivery across the blood-brain barrier. The company is developing novel treatments for brain disorders by combining existing drugs with its proprietary brain drug delivery platform. The company’s vision is that the treatment of currently unserved brain diseases will be best achieved by safely enhancing the blood-to-brain delivery of drugs.
to-BBB is headquartered in The Netherlands at the Leiden Bio Science Park and has established a fully owned subsidiary, to-BBB Taiwan Ltd., in Taipei, Taiwan.
SOURCE: to-BBB
Post Views: 72
